Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.87 |
| ▸ | CNR1 | P21554 | 11/20 | 0.87 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.87 |
| ▸ | LDHA | P00338 | 2/20 | 0.87 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.87 |
| ▸ | PPARG | P37231 | 1/20 | 0.87 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.62 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.62 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.62 |
| ▸ | TRPV5 | Q9NQA5 | 1/20 | 0.62 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.62 |
| ▸ | ABHD12 | Q8N2K0 | 3/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30325584 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL19422414 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL26487684 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL21119440 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL29784460 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL23210313 | 1.00 | CNR2 (0.87) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL23765126 | 0.94 | CNR2 (0.94) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL24704097 | 0.94 | CNR2 (0.94) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL29647762 | 0.94 | CNR2 (0.94) | CNR2CNR1TRPM8LDHADAGLA | |
| SCHEMBL13214131 | 0.94 | CNR2 (0.94) | CNR2CNR1TRPM8LDHADAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-3962296-B1 | CANNABINOID COMPOSITIONS AND METHODS OF USING | GREENWAY HERBAL PRODUCTS LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12582663-B2 | Compositions comprising decarboxylated cannabinoids | Natural Extraction Systems, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4678189-A2 | CANNABINOID COMPOSITIONS AND METHODS OF USING | Greenway Herbal Products, LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250122539-A1 | LARGE SCALE PRODUCTION OF DIVARIN, DIVARINIC ACID AND OTHER ALKYL RESORCINOLS BY FERMENTATION | LYGOS INC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250042838-A1 | PROCESS FOR THE SYNTHESIS AND PURIFICATION OF CANNABINOIC ACIDS AND ACYLATED DERIVATIVES THEREOF | TRESCO HOLDING GMBH (DE) | 2025-02-06 | — | — | US | disclosed |
| WO-2025003517-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | MABEWO PHYTOPHARM AG (CH) | 2025-01-02 | — | — | WO | disclosed |
| US-20240092752-A1 | GAS PHASE METHODS TO DECARBOXYLATE CANNABINOIDS | Natural Extraction Systems, LLC (US) | 2024-03-21 | — | — | US | disclosed |
| US-20240024340-A1 | Compositions and Methods For Treating Migraine | FISH & RICHARDSON P.C. | 2024-01-25 | — | — | US | disclosed |
| US-20240024340-A1 | Compositions and Methods For Treating Migraine | FISH & RICHARDSON P.C. | 2024-01-25 | — | — | US | disclosed |
| US-20140221469-A1 | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8790719-B2 | Phytocannabinoids in the treatment of cancer | GW PHARMA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-8790719-B2 | Phytocannabinoids in the treatment of cancer | GW PHARMA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| WO-2011110866-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | GW PHARMA LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221469-A1 | PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF CANCER | CNR2, BSG, CNR1 | CNR2 1/4885CNR1 3/4885TRPM8 1655/4885 |
| US-20240024340-A1 | Compositions and Methods For Treating Migraine | ACHE, GSK3B, HTR1B | CNR2 6/4885CNR1 16/4885TRPM8 276/4885 |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | CNR1, CNR2, LSS | CNR2 2/4885CNR1 1/4885TRPM8 2241/4885 |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | CNR2 1/4885CNR1 2/4885TRPM8 2766/4885 |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | CNR2 1/4885CNR1 2/4885TRPM8 2766/4885 |
| US-12582663-B2 | Compositions comprising decarboxylated cannabinoids | GGPS1, PGGT1B, CNR2 | CNR2 3/4885CNR1 8/4885TRPM8 2217/4885 |
| US-20250042838-A1 | PROCESS FOR THE SYNTHESIS AND PURIFICATION OF CANNABINOIC ACIDS AND ACYLATED DERIVATIVES THEREOF | CNR2, CNR1, PCCA | CNR2 1/4885CNR1 2/4885TRPM8 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.